BGI Genomics Co., Ltd. (300676.SZ) Latest Company News

Oct 29, 2026, 04:54 UTC
The Homeland Holding Corp. added BGI Genomics, MGI Tech and Shenzhen BGI Technology to the UFLPA Entity List, restricting their products from entering the U.S. market.
Source:
- finance.sina.cn
Oct 23, 2026, 10:53 UTC
BGI Genomics reported revenue of CNY 2.693 billion for the first three quarters of 2026, up 0.69% year over year, and attributable net profit of CNY 50.2797 million, reversing a year-earlier loss; adjusted net profit was CNY 13.151 million, also reversing a year-earlier loss.
Source:
- finance.sina.cn
Oct 23, 2026, 10:53 UTC
BGI Genomics reported third-quarter 2026 revenue of CNY 904 million, down 13.24% year over year, and attributable net profit of CNY 2.8751 million, compared with a loss a year earlier; adjusted net profit was CNY 4.7186 million, also reversing a year-earlier loss.
Source:
- finance.sina.cn
Sep 28, 2026, 09:15 UTC
Shenzhen Shenghua Investment Enterprise (Limited Partnership), a shareholder holding over 5% of BGI Genomics, released a pledge on 6.74 million shares and re-pledged 5.8 million shares to China CITIC Bank Shenzhen Branch for financing guarantee on 2026-09-24.
Source:
- finance.sina.cn
Sep 20, 2026, 12:26 UTC
BGI Genomics announced a partnership with JD Health at the 2026 JD Global Technology Explorer Conference, placing BGI Genomics' genetic testing products on the JD Health platform.
Source:
- finance.sina.cn
Aug 24, 2026, 11:55 UTC
BGI Genomics hosted a research visit by 8 institutions on August 24, 2026, with executives including director Zhao Lijian and general manager Hou Yong.
Source:
- wap.eastmoney.com
Aug 21, 2026, 15:34 UTC
BGI Genomics launched the Huayi series of intelligent terminals based on its self-developed GeneT large model, and introduced the SIRO high-throughput gene sequencing localized medical solution.
Source:
- wap.eastmoney.com
Aug 21, 2026, 10:58 UTC
BGI Genomics announced its 2026 half-year results, with net profit attributable to shareholders of 47.4046 million yuan, up 718.24% year-on-year.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 19, 2026, 08:43 UTC
BGI Genomics' controlling shareholder Shenzhen BGI Tech Solutions Co., Ltd. released a pledge on 7.6 million shares and re-pledged 6.9 million shares to China Merchants Bank Shenzhen Branch on August 18, 2026, for its own production and operation funding needs.
Source:
- finance.sina.cn
Aug 6, 2026, 09:34 UTC
BGI completed its third share buyback on August 5, 2026, repurchasing a total of 6,731,602 shares, representing 1.6092% of total share capital, for a total payment of 251 million yuan.
Source:
- finance.sina.cn
Aug 3, 2026, 09:30 UTC
BGI Genomics announced that as of July 31, 2026, it had repurchased 4.6201 million shares, representing 1.1045% of total share capital, for a total payment of 167 million yuan, and plans to continue executing the buyback program.
Source:
- finance.sina.cn
Jul 24, 2026, 11:16 UTC
BGI Genomics announced that its third-phase share buyback program has reached 1.0208% of total shares, spending 154 million yuan.
Source:
- finance.sina.cn
Jul 14, 2026, 08:28 UTC
BGI Genomics Co., Ltd. conducted its first share repurchase on July 13, 2026, buying back 1.5 million shares (0.3586% of total equity) for a total of RMB 54.2558 million.
Source:
- finance.sina.cn

300676.SZ

The Homeland Holding Corp. added BGI Genomics, MGI Tech and Shenzhen BGI Technology to the UFLPA Entity List, restricting their products from entering the U.S. market.

BGI Genomics reported revenue of CNY 2.693 billion for the first three quarters of 2026, up 0.69% year over year, and attributable net profit of CNY 50.2797 million, reversing a year-earlier loss; adjusted net profit was CNY 13.151 million, also reversing a year-earlier loss.

BGI Genomics reported third-quarter 2026 revenue of CNY 904 million, down 13.24% year over year, and attributable net profit of CNY 2.8751 million, compared with a loss a year earlier; adjusted net profit was CNY 4.7186 million, also reversing a year-earlier loss.

Shenzhen Shenghua Investment Enterprise (Limited Partnership), a shareholder holding over 5% of BGI Genomics, released a pledge on 6.74 million shares and re-pledged 5.8 million shares to China CITIC Bank Shenzhen Branch for financing guarantee on 2026-09-24.

BGI Genomics announced a partnership with JD Health at the 2026 JD Global Technology Explorer Conference, placing BGI Genomics' genetic testing products on the JD Health platform.

BGI Genomics hosted a research visit by 8 institutions on August 24, 2026, with executives including director Zhao Lijian and general manager Hou Yong.

BGI Genomics launched the Huayi series of intelligent terminals based on its self-developed GeneT large model, and introduced the SIRO high-throughput gene sequencing localized medical solution.

BGI Genomics announced its 2026 half-year results, with net profit attributable to shareholders of 47.4046 million yuan, up 718.24% year-on-year.

BGI Genomics' controlling shareholder Shenzhen BGI Tech Solutions Co., Ltd. released a pledge on 7.6 million shares and re-pledged 6.9 million shares to China Merchants Bank Shenzhen Branch on August 18, 2026, for its own production and operation funding needs.

BGI completed its third share buyback on August 5, 2026, repurchasing a total of 6,731,602 shares, representing 1.6092% of total share capital, for a total payment of 251 million yuan.

BGI Genomics announced that as of July 31, 2026, it had repurchased 4.6201 million shares, representing 1.1045% of total share capital, for a total payment of 167 million yuan, and plans to continue executing the buyback program.

BGI Genomics announced that its third-phase share buyback program has reached 1.0208% of total shares, spending 154 million yuan.

BGI Genomics Co., Ltd. conducted its first share repurchase on July 13, 2026, buying back 1.5 million shares (0.3586% of total equity) for a total of RMB 54.2558 million.